Why the study?
LVEF is widely used to determine ICD eligibility but is a better marker of total mortality than ventricular tachyarrhythmia mortality.
Do novel imaging tools and biomarkers improve sudden cardiac death risk stratification compared to LVEF alone in patients with dilated cardiomyopathy?
Do novel imaging tools and biomarkers improve sudden cardiac death risk stratification compared to LVEF alone in patients with dilated cardiomyopathy?
Multimodality imaging and novel biomarkers offer more precise sudden cardiac death risk stratification in non-ischemic cardiomyopathy than left ventricular ejection fraction alone.
May support refined SCD risk stratification beyond LVEF in DCM; leaves open prospective validation before practice change.
Implantable Cardioverter-Defibrillator (ICD) therapy is indicated for patients at risk for sudden cardiac death due to ventricular tachyarrhythmia. The most commonly used risk stratification algorithms use Left Ventricular Ejection Fraction (LVEF) to determine which patients qualify for ICD therapy, even though LVEF is a better marker of total mortality than ventricular tachyarrhythmias mortality. This review evaluates imaging tools and novel biomarkers proposed for better risk stratifying arrhythmic substrate, thereby identifying optimal ICD therapy candidates.
No takes yet. Share an insight, caveat, or question.
A 2021 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: